Clinical trials: Cardiovascular Event
Preoperative Care, Surgery--Complications
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting.
- Conditions
- Preoperative Care, Surgery--Complications, Myocardial Infarction
- Trial name
- VALIANCE (NCT04973397)
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Chest Pain, Acute Coronary Syndrome
Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
This multi-center, randomized, controlled trial conducted in Emergency Departments (ED) compares computed tomography (CT) coronary angiography with the traditional approach (usual care) for low- to intermediate-risk chest pain…
- Conditions
- Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
- Trial name
- NCT00933400
- Testing
- CT Coronary Angiography (CTCA), Traditional Strategy
- Where
- 5 sites in United States
- Volunteers
- 1,392 people
- Sponsor
- American College of Radiology
End-stage Renal Failure
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients.
- Trial name
- NCT01687699
- Testing
- Spironolactone
- Where
- Japan
- Volunteers
- 157 people
- Sponsor
- Dialysis Outcomes Heart Failure Aldactone Study Group
MACE, Cardiac Death
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform
The goal of this observational study is to observe the characteristics of cardiopulmonary exercise testing (CPET) parameters in patients across different cardiovascular diseases and to evaluate the predictive value of…
- Conditions
- MACE, Cardiac Death, Unplanned Repeat Revascularization, Cardiac Rehospitalization
- Trial name
- China-CPET (NCT07130968)
- Where
- China
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Patients on Anti-hypertensive Medication
Impact of a Procedure for the Information and Active Participation of the Patient in the Primary Care Prescription of Antihypertensives
Adverse drug events (ADEs) are responsible for 3.6% of the hospitalisations in France. 50% of these ADEs could be preventable. Cardiovascular drugs are frequently involved in ADEs.
- Trial name
- InPAct (NCT01610817)
- Testing
- InPAct : Information for Participating Actively in cardiovascular treatment
- Where
- France
- Volunteers
- 1,100 people
- Sponsor
- Hospices Civils de Lyon
COPD, COPD Exacerbation Acute
The Italian Registry of Patients With Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a treatable but debilitating medical condition associated with persistent symptoms and chronic airflow obstruction.
- Conditions
- COPD, COPD Exacerbation Acute, Comorbid Chronic Lung Disease on Heart Failure, Mortality
- Trial name
- ICoRe (NCT06652776)
- Testing
- Pharmacological treatment
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- University of Milan
Atrial Fibrillation
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
- Trial name
- SIFA (NCT00244426)
- Testing
- indobufen, aspirin
- Where
- 132 sites in Italy
- Volunteers
- 1,372 people
- Sponsor
- Pfizer
Cancer-associated Thrombosis, Genetic Predisposition
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy.
- Trial name
- ONCOTHROMB (NCT03114618)
- Where
- 9 sites in Spain
- Volunteers
- 416 people
- Sponsor
- Andres muñoz
Thromboembolic Events, Post-operative Bleeding
Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty.
There are many different views regarding ideal duration and type of thromboprophylaxis after hip or knee surgery. An important factor in Fast-track surgery is early mobilization, which in itself is thought to prevent clotting.
- Trial name
- FETA (NCT01557725)
- Where
- 6 sites in Denmark
- Volunteers
- 4,924 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Blood Pressure, Hypertension
PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health…
- Conditions
- Blood Pressure, Hypertension, Mhealth
- Trial name
- NCT03401489
- Testing
- PACESETTER
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Northern California Institute of Research and Education
Cardiac Event, Sudden Cardiac Death
To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients
In this study, we are comparing the difference in outcomes between patients who were given shocks to the heart, during the upstroke of cardiopulmonary resuscitation (CPR) and before CPR is started.
- Conditions
- Cardiac Event, Sudden Cardiac Death, Death, Ventricular Fibrillation
- Trial name
- NCT01665755
- Testing
- Upstroke Compression Defibrillation, Precompression Defibrillation
- Where
- Singapore
- Volunteers
- 180 people
- Sponsor
- Singapore General Hospital
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Acute Coronary Syndrome
Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome
To compare treatment with Aspirin Protect® twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect® 100 mg once per day on a composite end-point of ischemic events in diabetic patients, or in patients…
- Conditions
- Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease, Obesity
- Trial name
- ANDAMAN (NCT02520921)
- Testing
- Novel strategy Aspirin, Conventional strategy Aspirin
- Where
- France
- Volunteers
- 2,484 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertension, Stroke
A Cluster-Randomized Controlled Trial
The goal of this study is to learn if an AI-generated personalized health report combined with face-to-face guidance from cardiologists can help rural adults with high blood pressure control their blood pressure better and reduce…
- Conditions
- Hypertension, Stroke, Cardiovascular, Coronary Heart Disease
- Trial name
- NCT07845448
- Testing
- AI-powered personalized health report with cardiologist consultation and prescription optimization, Integrated management (follow-up, education, quality control) without AI report and cardiologist consultation
- Volunteers
- 14,400 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Neoplasms, Thrombosis
THrombo-Embolic Event in Onco-hematology
The overall incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) is 1 per 200 cancer patients, about 5 times higher than in the general population.
- Conditions
- Neoplasms, Thrombosis, Coagulation Disorder
- Trial name
- THEO (NCT03826043)
- Testing
- Blood sample analysis
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Antoine Lacassagne
Treatment of Lipoprotein Disorder
A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of HRS-5346 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- NCT06816264
- Testing
- HRS-5346
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Use of Incretins in Diabetic Patients
Observational, retrospective study, conducted in diabetic patients aimed to evaluate the effects on the glyco-metabolic control and on cardiovascular events of different DPP-4 inhibitors.
- Trial name
- NCT03486964
- Testing
- DPP-4 inhibitors
- Where
- Italy
- Volunteers
- 2,234 people
- Sponsor
- University of Pavia
Stroke, Post-stroke Cognitive Impairment (PSCI)
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Post-stroke cognitive impairment (PSCI) refers to a clinical syndrome characterized by cognitive impairment that occurs after a stroke event and persists for at least 24 weeks.
- Trial name
- Be-CLEVER (NCT05976152)
- Testing
- dl-3-butylphthalide
- Where
- China
- Volunteers
- 3,200 people
- Sponsor
- Fudan University
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.